7:00 – 8:00AM

Registration and Continental Breakfast

8:00 – 8:02AM

Welcome and Introduction

Elias Reichel, MD

8:03 – 8:23AM

Gene Therapy for Age-Related Macular Degeneration

Rajendra Kumar-Singh, PhD

8:24 – 8:44AM

Age-Related Macular Degeneration: Nature vs. Nurture Update 2008

Johanna M. Seddon, MD, ScM

8:45 – 9:05AM

Annual Rates of Arterial Thromboembolic Events in Medicare Neovascular AMD Patients

Anne E. Fung, MD

9:06 – 9:26AM

Dry AMD:  The Next Big Thing

Allen C. Ho, MD

9:2 – 9:47AM

A One Year Review of Practice Patterns with Ranibizumab for AMD in 10 National Centers

Anne E. Fung, MD

9:48 – 10:08AM

Discussion

10:09 – 10:29AM

Break

10:30 – 10:50AM

The CATT Trial:  Comparison of Age-Related Macular Degeneration Treatment Trials

Caroline R. Baumal, MD

10:51– 11:11AM

Bevacizumab for CNV not due to ARMD

Richard F. Spaide, MD

11:12 – 11:32AM

The Promise of Combination Therapy for Wet AMD

Carl D. Regillo, MD

11:33 – 11:53AM

New Therapies for AMD

Peter K. Kaiser, MD

11:54AM– 12:14PM

Is There a Role for Microplasmin in the Treatment of Exudative AMD?

Adam H. Rogers, MD

12:15 – 12:35PM

Socioeconomic Perspectives in the Treatment of ARMD

Carmen A. Puliafito, MD, MBA

12:36 – 12:56PM

Discussion

12:57 – 2:00PM

Lunch - Roundtable Discussions